Navigation Links
Argentum Medical Issues Response to Recent Decision in Litigation With Noble Biomaterials
Date:3/14/2011

CHICAGO, March 14, 2011 /PRNewswire/ -- Argentum Medical, LLC today issued a response to the recent decision in their patent infringement litigation versus Noble Biomaterials, Inc.

"The most important thing to know is the trial has no impact on our patents and it is business as usual for Argentum," said Gregg Silver, Chairman and CEO of Argentum Medical, LLC. "The case concerned non-patent issues and is currently being appealed. We are confident that our appeal will be successful."

Argentum Medical is an industry leader in antimicrobial silver dressings. The company manufactures more than 60 different combinations and sizes of Silverlon® products, and has developed 14 unique categories of wound, burn and post-surgical dressings. Argentum has sold more than three million dressings to more than 2,000 customers, including the Mayo Clinic, Johns Hopkins University, University of Michigan and the Department of Defense.

This month marks Argentum Medical's 10th anniversary. The company has experienced record sales in 2010, with the Silverlon Surgical Wound Pad and Island Dressings achieving domestic sales growth of more than 300% in the second half of the year.

Silver adds, "The litigation will not affect our customers. We will continue to provide our customers with Silverlon® and our other leading products. We are a financially strong company, and service to our customers will not be affected by any expenses resulting from this lawsuit."

Argentum prides itself on groundbreaking innovation, and has particular success with its Silverlon® Negative Pressure Dressing (NPD), which was named Innovative Product of the Year by Frost and Sullivan in 2006. NPD continues to be one of the company's fastest growing categories today. It was the first antimicrobial silver dressing designed to be utilized with negative pressure wound therapy.

About Argentum Medical

Headquartered in Chicago, Illinois, Argentum Medical is a leader in antimicrobial silver dressings. In early 2001, Argentum Medical was formed to commercialize patented and patent pending silver nylon technology. With the success of its burn products, the company diversified into other areas of wound care. Today, Argentum holds over 12 patents and is the only silver wound care company to manufacture over 60 different combinations and sizes for all aspects of acute and chronic patient care. For more information, visit www.silverlon.com.


'/>"/>
SOURCE Argentum Medical, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. D3 Oncology Solutions Now Includes Via Oncology Pathways for Medical Oncology
2. WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
3. Sensus Healthcare Announces the Formation of a Medical Advisory Board
4. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
5. Aethlon Medical to Present at the Wall Street Analyst Forum 22nd Annual Investor Conference
6. Cantel Medical Acquires the Sterilization Monitoring Business of ConFirm Monitoring Systems, Inc.
7. Larta Institute NIH Success Stories Featured in 2011 California Biomedical Industry Report
8. DiaTech Oncology and Walter Reed Army Medical Center Establish Pilot to Determine Best Chemotherapy for Cancer Patients
9. Gizmox Enters the Business Mobile Application Market - Visual WebGui Based Solutions Deployed in Major Financial and Medical Institutions
10. Californias Biomedical Industry is Poised for Growth Despite Increasing Global Competition, According to the 2011 California Biomedical Industry Report
11. Ingenuity Systems and Erasmus University Medical Center Collaborate on Next-Generation Sequencing Project to Accelerate Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way to ... technology experience. All three tenets were on display at the 2nd Annual DrugDev User ... 40 sponsor, CRO and site organizations to discuss innovation and the future of clinical ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 /PRNewswire/ ... of genomic services and solutions with cutting edge next-generation ... has completed a USD $75 Million [515 Million RMB] ... CMB International Capital Management ( Shenzhen ) ... Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment Center ...
Breaking Biology Technology:
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
Breaking Biology News(10 mins):